Meeting
2016 Genitourinary Cancers Symposium
Early tumor shrinkage under first-line tyrosine kinase inhibitor as a surrogate endpoint of overall survival in patients with metastatic renal cell carcinoma.
Authors
Hideaki Miyake
Kobe University Graduate School of Medicine, Kobe, Japan
Hideaki Miyake , Ken-ichi Harada , Masato Fujisawa
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session C: Renal Cell Cancer
Track
Renal Cell Cancer
Sub Track
Renal Cell Cancer
Citation
J Clin Oncol 34, 2016 (suppl 2S; abstr 523)
DOI
10.1200/jco.2016.34.2_suppl.523
Abstract #
523
Poster Bd #
E6
Abstract Disclosures
Similar Posters
Poster
2021 Genitourinary Cancers Symposium
Osteonecrosis of the jaw in metastatic renal cell carcinoma (mRCC) patients treated with zolendronic acid and denosumab: An observational retrospective multicenter trial.
First Author: Marco Stellato
Poster
2020 Genitourinary Cancers Symposium
Progression-free survival (PFS) and overall survival (OS) across ethnicities for patients with metastatic renal cell carcinoma (mRCC) receiving targeted therapies (TT) as first-line (1L) treatment.
First Author: Nicholas Salgia
Poster
2020 Genitourinary Cancers Symposium
Tivozanib as first-line treatment of metastatic renal cell carcinoma: A real-world outcome review in North-West of England, United Kingdom.
First Author: Sam Wong
Poster
2018 Genitourinary Cancers Symposium
Optimizing axitinib treatment selection following first-line sunitinib in metastatic renal cell carcinoma.
First Author: Sergio Bracarda